Shinhan Capital
VC Fund
Seoul, South Korea
Shinhan Capital is a credit-specialized company offering corporate finance services for its clients. It provides financial services, lease, corporate loans, investment financing, housing loans, installment financing, etc. Shinhan Capital was established in 1991. The company is headquartered in Seoul, South Korea.
- Total investments:
- 197
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries Shinhan Capital invests in
Stages Shinhan Capital invests in
Countries Shinhan Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Seed
- $347k–$4M
- Series A
- $2.1M–$13M
- Series B
- $3.7M–$18M
Investment Focus
Industry
- Information Technology 22 (11%)
- Software 15 (8%)
- E-Commerce 12 (6%)
- Health Care 12 (6%)
- Apps 11 (6%)
Stage
- Series A 47 (24%)
- Seed 33 (17%)
- Series B 33 (17%)
- Series C 8 (4%)
- Funding Round 8 (4%)
Country
- South Korea 108 (55%)
- United States 4 (2%)
- India 1 (1%)
- Japan 1 (1%)
- Iceland 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Heo Young Taeg
CEO
|
CEO | Total investments: 0 | Find email | |
|
Hyung-Seok Ha
Senior Manager
|
Senior Manager | Total investments: 1 | Find email | |
|
Lee Dong- hwan
directing manager
|
directing manager | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nventric
|
Nventric is a medical device company that develops core products for neurovascular, coronary heart, and peripheral vascular applications. | $22.6M / Venture - Series Unknown / Jun 10, 2026 | |
Spark Biopharma
|
SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring anddeveloping new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. ' | $21.4M / Venture - Series Unknown / May 11, 2026 | |
Mustbio
|
MustBio is a biotechnology company that leverages multi-antibody technology to develop therapeutics primarily in the field of immuno-oncology. The company was founded in 2021 and is based in Seoul, South Korea. | $23.3M / Series C / Mar 13, 2026 | |
Plastal
|
Plastal is a mechanical and chemical engineering company that offers polymer, metal, and mold injection services. The company specializes in using its core technology required for bonding between metal and plastic resin, mold technology, injection conditions, and milling capabilities, enabling manufacturing companies to avail themselves of theproducts they desire. | $13.1M / Series B / Oct 16, 2025 | |
IMBiologics
|
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M / Series C / Oct 14, 2025 | |
Novacos
|
Novacos develops cosmetic and skincare products through OEM and ODM manufacturing. The company handles formulation development, product production, packaging, quality control, and private-label cosmetics services. | $1.4M / Seed / Oct 01, 2025 | |
Rose Lab
|
Rose Lab is a bioremediation and cosmetic medical device manufacturing company that provides research on bioremediation products. The company aims to become a specialized medical company leading the development of innovative materials for safe clinical application and the convergence of medicine, life science, polymer chemistry, and newtechnologies, for the health and beautiful lives of humanity. Rose Lab solve problems through a shift in perspective and creative thinking. | $7.2M / Series B / Sep 01, 2025 | |
Trioar
|
Trioar is a biotechnological research company that manufacture pharmaceutical products and drugs. | $16.2M / Series B / Jul 17, 2025 | |
Curiosis
|
Curiosis’s expert team of scientists and engineers are dedicated to develop high efficiency instruments by using core technologies of biophysics and electronic engineering. Providing cutting edge technologies and optimized platform allow the researchers to challenging their progress improvement. | $9.6M / Oct 14, 2024 | |
Global Technologies
|
Global Technologies specializes in developing core sensors and advanced sensor systems. Leveraging proprietary semiconductor and software technology, they provide high-performance solutions for environmental sensing and industrial applications. Based in Korea, the company focuses on innovation in sensor hardware to enable smarter data collectionand automation across various global markets. | $9.4M / Series A / Jul 04, 2024 | |
| See all 197 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Shinhan Capital invest in?
Shinhan Capital invests primarily in Information Technology, Software and E-Commerce startups, most often at Series A and Seed stage. Most of the 197 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Shinhan Capital's check size?
Shinhan Capital typically joins rounds of $347k–$4M at Seed, $2.1M–$13M at Series A and $3.7M–$18M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shinhan Capital participates in.
How do I contact Shinhan Capital?
Public channels for Shinhan Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shinhan Capital?
The team at Shinhan Capital includes Heo Young Taeg (CEO), Hyung-Seok Ha (Senior Manager) and Lee Dong- hwan (directing manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
